We are live on
!
Find out more
WCM Investment Management Portfolio holdings
AUM
$43.8B
1-Year Est. Return
42.28%
This Fund
S&P 500
This Quarter
Est. Return
+11.37%
1 Year Est. Return
+42.28%
3 Year Est. Return
+149.38%
5 Year Est. Return
+174.91%
10 Year Est. Return
+944.06%
AUM
$39.4B
AUM Growth
+$2.86B
(+7.8%)
Cap. Flow
-$568M
Cap. Flow
% of AUM
-1.44%
Top 10 Holdings %
Top 10 Hldgs %
60.47%
Holding
212
New
22
Increased
129
Reduced
29
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPAM Systems
EPAM
|
+$1.33B |
| 2 |
Entegris
ENTG
|
+$289M |
| 3 |
Stryker
SYK
|
+$146M |
| 4 |
Sherwin-Williams
SHW
|
+$144M |
| 5 |
Old Dominion Freight Line
ODFL
|
+$141M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$717M |
| 2 |
ASML
ASML
|
+$583M |
| 3 |
Accenture
ACN
|
+$527M |
| 4 |
HDFC Bank
HDB
|
+$499M |
| 5 |
Smith & Nephew
SNN
|
+$308M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.58% |
| 2 | Healthcare | 23.05% |
| 3 | Consumer Discretionary | 15.14% |
| 4 | Financials | 10.85% |
| 5 | Industrials | 10.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Tandem Diabetes Care
TNDM
$1.59B
| $10M | 0.03% |
102,626
+32,475
| +46% | +$2.9M |
|
127
APi Group
APG
$18.1B
| $9.24M | 0.02% |
+663,365
| New | +$9.41M |
|
128
CryoPort
CYRX
$740M
| $8.95M | 0.02% |
141,816
+7,420
| +6% | +$418K |
|
129
Maximus
MMS
$2.99B
| $8.13M | 0.02% |
92,457
+3,587
| +4% | +$329K |
|
130
Fate Therapeutics
FATE
$326M
| $8.08M | 0.02% |
93,120
+3,696
| +4% | +$298K |
|
|
CCF
131
DELISTED
Chase Corporation
CCF
| $8.03M | 0.02% |
78,248
+4,736
| +6% | +$524K |
|
|
BHVN
132
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $7.98M | 0.02% |
82,213
+3,271
| +4% | +$265K |
|
|
NSTG
133
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.87M | 0.02% |
121,397
+28,525
| +31% | +$1.81M |
|
134
Caesars Entertainment
CZR
$6.14B
| $7.52M | 0.02% |
72,462
-114,723
| -61% | -$11.6M |
|
135
Arrowhead Research
ARWR
$12.3B
| $7.24M | 0.02% |
87,432
+3,383
| +4% | +$252K |
|
136
Ultragenyx Pharmaceutical
RARE
$2.59B
| $6.95M | 0.02% |
72,906
+2,841
| +4% | +$296K |
|
137
Elastic
ESTC
$7.86B
| $6.21M | 0.02% |
42,639
+38,151
| +850% | +$4.77M |
|
138
Halozyme
HALO
$12.3B
| $6.14M | 0.02% |
135,148
+5,225
| +4% | +$231K |
|
139
Axsome Therapeutics
AXSM
$11.1B
| $4.96M | 0.01% |
73,598
+2,934
| +4% | +$176K |
|
140
Insmed
INSM
$28.6B
| $4.54M | 0.01% |
159,499
+6,350
| +4% | +$188K |
|
141
Rocket Pharmaceuticals
RCKT
$399M
| $4.29M | 0.01% |
96,801
+3,811
| +4% | +$166K |
|
|
TPTX
142
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.24M | 0.01% |
54,315
+2,084
| +4% | +$154K |
|
143
BridgeBio Pharma
BBIO
$16.7B
| $3.96M | 0.01% |
65,022
-40,406
| -38% | -$2.31M |
|
144
Iovance Biotherapeutics
IOVA
$2.85B
| $3.92M | 0.01% |
150,839
+83,694
| +125% | +$2.18M |
|
145
Ligand Pharmaceuticals
LGND
$6.45B
| $3.92M | 0.01% |
47,963
+1,755
| +4% | +$146K |
|
|
RETA
146
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.76M | 0.01% |
26,576
-14,383
| -35% | -$1.62M |
|
147
Azenta
AZTA
$1.5B
| $3.69M | 0.01% |
+38,762
| New | +$3.76M |
|
148
Amazon
AMZN
$2.98T
| $3.68M | 0.01% |
21,380
| – | – |
|
149
Phathom Pharmaceuticals
PHAT
$711M
| $3.52M | 0.01% |
+103,987
| New | +$3.72M |
|
150
NetEase
NTES
$84.3B
| $3.32M | 0.01% |
28,784
+25,870
| +888% | +$2.85M |
|
Similar funds
LP
WCM Investment Management's Q2 2021 Portfolio in Review
As of Q2 2021, WCM Investment Management held 212 positions worth $39.4B, up 7.8% from $36.5B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
WCM Investment Management's Q2 2021 filing shows 22 new, 129 increased, 29 reduced and 16 closed positions. Its largest new stake was Entegris: 2,516,144 shares worth $309M. The largest sale was TSMC, an estimated $717M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- WCM Investment Management's largest Q2 2021 buy was Entegris: 2,516,144 shares worth $309M.
- WCM Investment Management added most to EPAM Systems in Q2 2021, an estimated $1.33B increase.
- WCM Investment Management's biggest Q2 2021 reduction was TSMC, cutting an estimated $717M.
- WCM Investment Management fully exited Ecolab in Q2 2021, selling an estimated $294M.
- WCM Investment Management's ten largest holdings make up 60% of its $39.4B portfolio in Q2 2021.
- WCM Investment Management opened 22 new positions and closed 16 in Q2 2021.
- WCM Investment Management's portfolio value rose 7.8% quarter-over-quarter to $39.4B.
Based on WCM Investment Management's 13F filing for Q2 2021, filed 5 Aug 2021.